Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tauroursodeoxycholic Acid (TUDCA) Clear all
Terminated Not applicable Interventional

Effects of TUDCA on Endothelial Function in Type 2 DM

NCT03462940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Response, Endothelial Dysfunction
Interventions
Tauroursodeoxycholic acid
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 24, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)

NCT07699380
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
Interventions
AMX0035, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 24, 2026, 4:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Endoplasmic Reticulum Stress in Human Hypertension

NCT06025630
View directory record Official record
Conditions
Hypertension
Interventions
TUDCA, Placebo
Drug
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function

NCT03331432
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tauroursodeoxycholic acid, Placebo
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
20 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance

NCT01877551
View directory record Official record
Conditions
HIV Related Insulin Resistance, Protease Inhibitor Related Insulin Resistance, Endoplasmic Reticulum Stress
Interventions
Tauroursodeoxycholic acid, Placebo tablet
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

NCT00004441
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
tauroursodeoxycholic acid, ursodiol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

NCT03533257
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AMX0035, Placebo
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Jacksonville, Florida • Orlando, Florida • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2Phase 3 Interventional

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
View directory record Official record
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TUDCA as a Therapy for Ulcerative Colitis (UC)

NCT04114292
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tauroursoursodeoxycholic acid, brand name Tudcabil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
Creve Coeur, Missouri • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 24, 2026, 4:42 PM EDT
Approved For Marketing No phase listed Expanded access

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

NCT05286372
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 24, 2026, 4:42 PM EDT
Not listed Phase 3 Interventional

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

NCT05021536
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, AMX0035
Other · Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2Phase 3 Interventional

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04516096
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

NCT02218619
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tauroursodeoxycholic Acid (TUDCA), Sugar Pill (placebo)
Drug
Lead sponsor
Robin Goland, MD
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 24, 2026, 4:42 PM EDT
Not yet recruiting Phase 2 Interventional

Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.

NCT07457632
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Tauroursodeoxycholate (TUDCA), Traditional Chinese Medicine (mQJDHW), placebo capsule
Dietary Supplement · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Endoplasmic Reticulum Stress on Metabolic Function

NCT00771901
View directory record Official record
Conditions
Insulin Resistance, Diabetes, Obesity
Interventions
tauroursodeoxycholic acid, placebo, sodium phenylbutyrate
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 24, 2026, 4:42 PM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 24, 2026, 4:42 PM EDT
Not listed Phase 1Phase 2 Interventional

Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

NCT04987671
View directory record Official record
Conditions
ALS
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03127514
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

NCT03423121
View directory record Official record
Conditions
Progressive Multiple Sclerosis
Interventions
Tauroursodeoxycholic Acid, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 24, 2026, 4:42 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Targeting ER Stress in Vascular Dysfunction

NCT04001647
View directory record Official record
Conditions
Vasodilation, Arterial Stiffness
Interventions
Acetylcholine, Sodium Nitroprusside, Ascorbic Acid
Drug
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Open Label Extension Study of AMX0035 in Patients With ALS

NCT03488524
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 24, 2026, 4:42 PM EDT
Completed No phase listed Observational

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896
View directory record Official record
Conditions
Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 24, 2026, 4:42 PM EDT
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Sep 24, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

NCT01855360
View directory record Official record
Conditions
Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Interventions
Tauroursodeoxycholic Acid and Doxycycline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 24, 2026, 4:42 PM EDT